| Name | Title | Contact Details |
|---|
The Y. For a better us.
MD Care Inc is a Los Alamitos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Groups360™️ was founded in 2014 with the goal of simplifying and transforming the ways meetings are booked. The company`s search engine, GroupSync™️, using its proprietary matching algorithms designed specifically for meeting planners, has helped place thousands of events at the right venue, saving planners time and money. GroupSync`s price predictor tool delivers improved transparency, reducing time and effort required to book meetings for both the hotel and the planner. Groups360`s management team has decades of experience in the meetings and events industry and provides the right mix of technology and experienced advisors. Using GroupSync, planners can search more than 200,000 properties in 225 countries and territories.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
Offering the benefits of resort-style amenities and an independent lifestyle, with access to award-winning lifecare services providing added peace of mind.